D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
A Phase II Trial of Etoposide, Leucovorin, 5-FU, and Interferon Alpha 2b (ELFI) + G-CSF for Patients with Pancreatic Adenocarcinoma: a Southwest Oncology Group Study (SWOG 9413)
John S. Macdonald,Joth Jacobson,Manuel Modiano,Dennis F. Moore,David R. Gandara,Louis E. Schroder,Robert Chapman +6 more
TL;DR: Although the combination of ELF and interferonalpha 2b (ELFI) has modest activity in pancreatic cancer, it is a toxic and complex regimen that is not superior to othercurrently available approaches for the chemotherapeuticmanagement of pancreaticcancer.
Journal ArticleDOI
Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer.
L. Renee Ruhaak,L. Renee Ruhaak,Carol Stroble,Jianliang Dai,Matt J. Barnett,Ayumu Taguchi,Gary E. Goodman,Suzanne Miyamoto,David R. Gandara,Ziding Feng,Carlito B. Lebrilla,Samir M. Hanash +11 more
TL;DR: The predictive value of serum glycans to distinguish non–small cell lung cancer cases from controls in prediagnostic samples using a previously validated predictive protein marker pro-SFTPB, as anchor, is determined.
Journal ArticleDOI
Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST).
Nicholas P. Campbell,Kristen Wroblewski,Robert G. Maki,D. R. D'Adamo,Warren Chow,David R. Gandara,C. R. Antonescu,Walter M. Stadler,E. E. Vokes,Hedy L. Kindler +9 more
TL;DR: SOR is active in IM-and SU-resistant GIST pts, but dose reductions are often required, and some pts treated with SOR experience prolonged disease control.
Journal ArticleDOI
Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.
Charu Aggarwal,Mary W. Redman,Primo N. Lara,Hossein Borghaei,Philip C. Hoffman,Jeffrey D. Bradley,Katie Griffin,Jieling Miao,Philip C. Mack,Vassiliki A. Papadimitrakopoulou,Roy S. Herbst,Karen Kelly,David R. Gandara +12 more
TL;DR: S1400D is a phase II biomarker-driven therapeutic sub-study evaluating the FGFR inhibiting substance in patients with SqNSCLC who have previously been treated with FGFR antagonists.
Journal ArticleDOI
Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
George Somlo,Paul Frankel,Thehang Luu,Cynthia X. Ma,Banu Arun,Agustin A. Garcia,Tessa Cigler,Leah Cream,Harold A. Harvey,Joseph A. Sparano,Rita Nanda,Helen K. Chew,Timothy J. Moynihan,Linda T. Vahdat,Matthew P. Goetz,Arti Hurria,Joanne E. Mortimer,David R. Gandara,Alice P. Chen,Jeffrey N. Weitzel +19 more
TL;DR: This paper describes single agent vel activity and, upon progression, the feasibility and efficacy of continuing administration of vel + carb and describes a phase I trial showing 54% confirmed partial response (PR) with carb + vel.